{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8093288_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"114-919-020-919-856"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10801,"type":"PATENT","title":"Boston University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4398,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8266,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"Boston Univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3218
Search Applicants and Owners separately: \"Boston Univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3218
i) administering to the mammal a compound represented by the following structural formula:\n\nor pharmaceutically acceptable salts thereof, wherein:\n
— — — — is a single or double bond;\n
X1 is ═CR18—, X2 is ═CR12—, and X3 is CR13R14; X2 is ═CR18—, X3 is ═CR12—, and X1 is CR13R14; or X1 is CR6R7, X2 is CR8R9 and X3 is CR10R11;\n
X4 is —O— or —NR′—;\n
R′ is H or a C1-C5 alkyl;\n
R1 is —H, —OH, ═O, —OSi(R19)3, a hexose or pentose; or R1, taken together with a substituent of X3 selected from R10, R11, R12, R13, R14, and R18, together with C7a, the carbon to which R1 is attached, and the carbon represented by X3, form a cyclic ether;\n
R2 is —OR, or —NR4R5; or when X1 is CR13R14, R2 and R13, together with C4, C4a, the carbon to which R13 is attached and the carbonyl group to which R2 is attached, form a lactone ring;\n
R is H or a C1-C5 alkyl;\n
R3 is —H, —OH, or —OR, or, optionally when — — — — is a single bond, ═O;\n
R4 and R5 are each, independently, —H or a C1-C5 alkyl; or R4 and R5 together with the nitrogen to which they are attached form a heterocyclic ring, wherein the C1-C5 alkyl or the heterocyclic ring are optionally substituted with one or more of hydroxy, a halo, a C1-C5 alkyl, phenyl, or cyano;\n
R6, R7, R8, R9, R10, R11, R13, R14 and R99 are independently —H, —OH, —F, —Cl, —Br, —I, —NO2, —NR2, —C(O)NR2, a C1-C5 alkyl, a hydroxyalkyl, —CH2OC(O)NR15R16, or —CH2OC(O)R17; or R13 and R14 together are ═O; or R8 and R10 together with two adjacent carbons to which they are attached, form an epoxy ring; or R6 and R8 together with two adjacent carbons to which they are attached, form an epoxy ring;\n
R12 and R18 are each, independently, —H, a C1-C5 alkyl, hydroxyalkyl, —CH2OC(O)NR15R16, —CH2OC(O)R17, or —CH2OH;\n
R15 and R16 are each, independently, —H or a C1-C5 alkyl;\n
R17 is a C1-C5 alkyl; and\n
R19 for each occurrence is, independently, a C1-C5 alkyl or an aryl, provided that\n\n\nwhen X4 is —O—, R2 is —OCH3, and R1 is ═O, —OH, —OC(O)CH3, glucosyl, O-tetraacetylglucosyl, O-tetramethylglucosyl, or t-butyldimethylsiloxy, and X3 is ═CR12 or CR10R11, then none of R10, R11, or R12 is —CH2OH, —CH2OC(O)CH3, or —CH3;\nwhen X4 is —O—, R2 is —OCH3, and R1 is —H, ═O, —OH or t-butyldimethylsiloxy, and X3 is CR10R11, then none of R10 and R11 is —CH2OH, and R10 and R11 are not both —H; and\nthe compound is not\n
ii) administering to the mammal a compound represented a structural formula selected from:\n\nor pharmaceutically acceptable salts thereof, wherein:\n
ring A is optionally substituted with one or more of —OH, a halo, nitro, cyano, or carboxy;\n
X4 is —O— or —NR—;\n
R is H or a C1-C5 alkyl;\n
R1 is —OH, ═O, —OSi(R19)3, a hexose or pentose;\n
R20 is —OR, or —NR4R5; and\n
R4 and R5 are each, independently, —H or a C1-C5 alkyl; or R4 and R5 together with the nitrogen to which they are attached form a heterocyclic ring, wherein the C1-C5 alkyl or the heterocyclic ring are optionally substituted with one or more of hydroxy, a halo, a C1-C5 alkyl, phenyl, or cyano."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is represented by the following structural formula:\nwherein:\n
X1 is ═CR18—, X2 is ═CR12—, and X3 is CR13R14; X2 is ═CR18—, X3 is ═CR12—, and X1 is CR13R14; or X1 is CR6R7, X2 is CR8R9 and X3 is CR10R11;\n
X4 is —O— or —NR—;\n
R is H or a C1-C5 alkyl;\n
R1 is —OH, ═O, —OSi(R19)3, a hexose or pentose;\n
R2 is —OR, or —NR4R5; or when X1 is CR13R14, R2 and R13, together with C4, C4a, C5, the carbon to which R13 is attached and the carbonyl group to which R2 is attached, form a five membered lactone ring;\n
R4 and R5 are each, independently, —H or a C1-C5 alkyl; or R4 and R5 together with the nitrogen to which they are attached form a heterocyclic ring, wherein the C1-C5 alkyl or the heterocyclic ring are optionally substituted with one or more of hydroxy, a halo, a C1-C5 alkyl, phenyl, or cyano;\n
R6, R7, R8, R9, R10, R11, R13 and R14 are independently —H, —OH, a C1-C5 alkyl, a hydroxyalkyl, —CH2OC(O)NR15R16, —CH2OC(O)R17, or —CH2OH; or R13 and R14 together are ═O; or R8 and R10 together with two adjacent carbons to which they are attached, form an epoxy ring;\n
R12 and R18 are each, independently, —H, a C1-C5 alkyl, hydroxyalkyl, —CH2OC(O)NR15R16, —CH2OC(O)R17, or —CH2OH;\n
R15 and R16 are each, independently, —H or a C1-C5 alkyl;\n
R17 is a C1-C5 alkyl; and\n
R19 for each occurrence is, independently, a C1-C5 alkyl or an aryl."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is represented by the following structural formula:"],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is represented by the following structural formula:\nwherein:\n
X5 is ═CR18—, X2 is ═CR12—, and X3 is CR13R14; X2 is ═CR18—, X3 is ═CR12—, and X5 is CR21R22; or X1 is CR6R7, X2 is CR8R9 and X3 is CR10R11; and\n
R21 and R22 are independently —H, —OH, a C1-C5 alkyl, a hydroxyalkyl, —CH2OC(O)NR15R16, —CH2OC(O)R17, or —CH2OH; or R21 and R22 together are ═O."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is represented by the following structural formula:\nwherein:\n
R2 is —OR, or —NR4R5; and\n
R23, R24, R25, R26 are independently —H, —OH, a C1-C5 alkyl, a hydroxyalkyl, —CH2OC(O)NR15R16, —CH2OC(O)R17, or —CH2OH, provided that when R1 is glucosyl and R25 is —H, R26 is not methyl."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the non-insulin dependent diabetes mellitus is the early stages of non-insulin dependent diabetes mellitus."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is represented by a structural formula selected from:"],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is represented by a structural formula selected from"],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is represented by the following structural formula:"],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is represented by the following structural formula:"],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is represented by the following structural formula:"],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating a disorder selected from deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, or a combination of deficient first-phase insulin secretion and non-insulin dependent diabetes mellitus in a mammal, comprising administering to the mammal a compound represented by:\n
or pharmaceutically acceptable salts thereof, wherein:\n
— — — — is a single or double bond;\n
X1 is CR6R7, X2 is CR8R9 and X3 is CR10R11;\n
X4 is —O—;\n
R1 taken together with a substituent of X3 selected from R10, R11, together with C7a, the carbon to which R1 is attached, and the carbon represented by X3, form a cyclic ether; and R2 is —OR or —NR4R5;\n
R is independently H or a C1-C5 alkyl;\n
R3 is —H, —OH, or —OR, or, optionally when — — — — is a single bond, ═O;\n
R4 and R5 are each, independently, —H or a C1-C5 alkyl; or R4 and R5 together with the nitrogen to which they are attached form a heterocyclic ring, wherein the C1-C5 alkyl or the heterocyclic ring are optionally substituted with one or more of hydroxy, a halo, a C1-C5 alkyl, phenyl, or cyano;\n
R6, R7, and R10 are independently selected from the group consisting of —H, —OH, —F, —Cl, —Br, —I, —NO2, —NR2, —C(O)NR2, a C1-C5 alkyl, a hydroxyalkyl, —CH2OC(O)NR15R16, and —CH2OC(O)R17; or R8 and R10 together with two adjacent carbons to which they are attached, form an epoxy ring; or R6 and R8 together with two adjacent carbons to which they are attached, form an epoxy ring;\n
R8, R9 and R11 are independently selected from the group consisting of —H, —OH, —F, —Cl, —Br, —I, a C1-C5 alkyl and a hydroxyalkyl;\n
R15 and R16 are each, independently, —H or a C1-C5 alkyl; and\n
R17 is a C1-C5 alkyl, provided that the compound is not"],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating a disorder selected from deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, or a combination of deficient first-phase insulin secretion and non-insulin dependent diabetes mellitus in a mammal, comprising administering to the mammal a compound represented by a structural formula selected from:"],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein the compound is represented by a compound represented by a structural formula selected from:"],"number":14,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}